NZ515049A - Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof - Google Patents

Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof

Info

Publication number
NZ515049A
NZ515049A NZ515049A NZ51504900A NZ515049A NZ 515049 A NZ515049 A NZ 515049A NZ 515049 A NZ515049 A NZ 515049A NZ 51504900 A NZ51504900 A NZ 51504900A NZ 515049 A NZ515049 A NZ 515049A
Authority
NZ
New Zealand
Prior art keywords
tumor formation
precursors
deoxyglucosone
susceptibility
reducing
Prior art date
Application number
NZ515049A
Inventor
Truman R Brown
Francis Kappler
Steven H Seeholzer
Original Assignee
Fox Chase Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fox Chase Cancer Ct filed Critical Fox Chase Cancer Ct
Publication of NZ515049A publication Critical patent/NZ515049A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels in high fructose corn syrup so that the high fructose corn syrup is less likely to induce tumor formation.
NZ515049A 1999-04-15 2000-04-17 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof NZ515049A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12941599P 1999-04-15 1999-04-15
PCT/US2000/010071 WO2000062626A1 (en) 1999-04-15 2000-04-17 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof

Publications (1)

Publication Number Publication Date
NZ515049A true NZ515049A (en) 2004-12-24

Family

ID=22439828

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515049A NZ515049A (en) 1999-04-15 2000-04-17 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof

Country Status (8)

Country Link
EP (1) EP1175155A4 (en)
AU (1) AU777745B2 (en)
CA (1) CA2369755A1 (en)
HK (1) HK1040164A1 (en)
IL (2) IL145957A0 (en)
MX (1) MXPA01010489A (en)
NZ (1) NZ515049A (en)
WO (1) WO2000062626A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290929B1 (en) * 2000-07-28 2001-09-18 The Procter & Gamble Company Cancer treatment
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
SE523153C2 (en) * 2000-12-28 2004-03-30 Gambro Lundia Ab Method of detoxification of medical solution
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
US9051583B2 (en) 2011-12-19 2015-06-09 Northwestern University Modified silica shell particles, and methods of making and using the same
WO2017210580A1 (en) * 2016-06-03 2017-12-07 Enlibrium, Inc. Imidodicarbonimidic diamide analogs

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221683A (en) * 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US5476849A (en) * 1984-03-19 1995-12-19 The Rockefeller University Methods for glycosylation inhibition using amino-benzoic acids and derivatives
US5358960A (en) * 1984-03-19 1994-10-25 The Rockefeller University Method for inhibiting advanced glycosylation of proteins using aminosubstituted imidazoles
US5258381A (en) * 1984-03-19 1993-11-02 The Rockefeller University 2-substituted-2-imidazolines
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5130324A (en) * 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5114943A (en) * 1984-03-19 1992-05-19 The Rockefeller University Amino-substituted pyrimidines, derivatives and methods of use therefor
US5468777A (en) * 1984-03-19 1995-11-21 The Rockefeller University Method and agents for preventing and reversing the staining of teeth
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
US5272165A (en) * 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5534540A (en) * 1984-03-19 1996-07-09 Alteon Inc. Methods of inhibiting the advanced glycosylation of proteins using tetramic and tetronic acids and compositions therefor
US5262152A (en) * 1984-03-19 1993-11-16 The Rockefeller University Amidrazones and derivatives thereof
US5318982A (en) * 1984-03-19 1994-06-07 The Rockefeller University Inhibition of the advanced glycosylation of proteins using substituted-1,2,4-triazoles
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
US5100919A (en) * 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5094694B1 (en) * 1987-03-31 1995-07-11 Dow Chemical Co Process for demineralizing a sugar-containing solution
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5518720A (en) * 1992-12-30 1996-05-21 Exocell, Inc. Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US5500439A (en) * 1993-12-09 1996-03-19 Alteon Inc. Aminopyrazoles
US5698563A (en) * 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
US5661139A (en) * 1995-01-13 1997-08-26 Alteon Inc. Bis-(2-aryl) hydrazones
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
US5850840A (en) * 1995-11-15 1998-12-22 Alteon Inc. Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
EP0877943A1 (en) * 1995-12-26 1998-11-18 The Picower Institute For Medical Research Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
JPH10182460A (en) * 1996-12-27 1998-07-07 Nippon Zoki Pharmaceut Co Ltd 3-deoxyglucosone generation inhibitor
US6004958A (en) * 1997-02-05 1999-12-21 Fox Chase Cancer Center Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
CN1331599A (en) * 1998-10-28 2002-01-16 福克斯契思癌症中心 Compounds and their therapeutic use with diabetic complications

Also Published As

Publication number Publication date
EP1175155A1 (en) 2002-01-30
WO2000062626A1 (en) 2000-10-26
IL145957A0 (en) 2002-07-25
HK1040164A1 (en) 2002-05-31
CA2369755A1 (en) 2000-10-26
AU4350100A (en) 2000-11-02
MXPA01010489A (en) 2002-05-06
IL145957A (en) 2007-02-11
EP1175155A4 (en) 2005-10-19
AU777745B2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
CA2282654A1 (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
AP2001002319A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003225295A1 (en) Substituted pyrroline kinase inhibitors
MY169308A (en) Treatment of tnf? related disorders
GR3037074T3 (en) Protein kinase c inhibitors
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
WO2004108157A3 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
EP1565136A4 (en) Compositions and methods for transdermal oxybutynin therapy
GR20010300033T1 (en) Raf kinase inhibitors
NZ326754A (en) The use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene or salts thereof for the prophylaxis and treatment of sequelae of chronic reduced circulation in the brain in particular strokes and for neurodegenerative disorders
TW200626131A (en) C-aryl glucoside SGLT2 inhibitors and method
ZA200109903B (en) Method for treating chronic pain using MEK inhibitors.
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
HUP0200026A2 (en) Method for treating exercise induced asthma
MX340217B (en) Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor.
TNSN04015A1 (en) Combination therapy for the treatment of cancer
ES2088771A1 (en) Method for improving breeding activity of boars by using feed for the breeding boars
NZ515049A (en) Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
MY114942A (en) Method for treatment of chronic bronchitis using indole compounds
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
WO2004071413A3 (en) Method and composition for potentiating an opiate analgesic

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed